Identification of promiscuous small molecule activators in high-throughput enzyme activation screens.

It is recognized that high-throughput enzyme inhibition screens often return nonspecific inhibitors as "hits". Recently, high-throughput screens for enzyme activators have led to the identification of several compounds with novel and potent biological activity. Here, we show that enzyme activation screens can also uncover compounds that activate multiple enzymes in a nonspecific fashion. Described herein are the general structural features of such compounds and methods to differentiate between specific and general enzyme activation.

[1]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[2]  D. Pereira,et al.  Origin and evolution of high throughput screening , 2007, British journal of pharmacology.

[3]  R. Silverman,et al.  Small-molecule activators of RNase L with broad-spectrum antiviral activity , 2007, Proceedings of the National Academy of Sciences.

[4]  The dual role of CHAPS in the crystallization of stromelysin-3 catalytic domain. , 2003, Acta crystallographica. Section D, Biological crystallography.

[5]  J. Broach,et al.  High-throughput screening for drug discovery. , 1996, Nature.

[6]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[7]  B. Shoichet.  Screening in a spirit haunted world. , 2006, Drug discovery today.

[8]  P. Hergenrother,et al.  Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy , 2006, Nature chemical biology.

[9]  E. G. Delmar,et al.  A sensitive new substrate for chymotrypsin. , 1979, Analytical biochemistry.

[10]  Brian K Shoichet,et al.  A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.

[11]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[12]  J. Lakowicz,et al.  On the effect of sodium dodecyl sulfate on the structure of beta-galactosidase from Escherichia coli. A fluorescence study. , 2001, Journal of biochemistry.

[13]  J. Mankovich,et al.  Substrate Specificities of Caspase Family Proteases* , 1997, The Journal of Biological Chemistry.

[14]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[15]  Paul J Hergenrother,et al.  Obtaining and screening compound collections: a user's guide and a call to chemists. , 2006, Current opinion in chemical biology.

[16]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[17]  B. Posner,et al.  High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. , 2005, Current opinion in drug discovery & development.

[18]  Amy V. Lynch,et al.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.

[19]  J. Grimsby,et al.  Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. , 2006, Current medicinal chemistry.

[20]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[21]  J. Grippo,et al.  Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.